Influence of dentures on residual inhaled corticosteroids in the mouths of elderly asthma patients

Respiratory Investigation

Volumn 50, Issue 2, 2012, Pages 54-61

  Ohbayashi, Hiroyuki ^a,b   Adachi, Mitsuru ^a  

^a Tohno Chuo Clinic   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Asthma; Denture; Gargling; Inhaled corticosteroid

Indexed keywords

ANDROSTANE DERIVATIVE; BECLOMETASONE; BRONCHODILATING AGENT; FLUORINATED HYDROCARBON; FLUTICASONE; MOUTHWASH; NORFLURANE;

AGED; ASTHMA; CANDIDIASIS, ORAL; CHEMISTRY; DENTURE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MOUTH; VERY ELDERLY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; CANDIDIASIS, ORAL; DENTURES; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MOUTH; MOUTHWASHES;

EID: 84868275043     PISSN: 22125345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resinv.2012.05.001     Document Type: Article

References (14)

1. Edsbäcker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999, 58(Suppl. 4):7-16.
2. Melani A.S. Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 2007, 78:233-245.
3. Banno M., Ibata H., Niimi T., et al. The usefulness of inspiratory flow rate during inhalation corticosteroid therapy in asthma. Respiration 2009, 78:387-392.
4. Kurt E., Yildirim H., Kiraz N., et al. Oropharyngeal candidiasis with dry-powdered fluticasone propionate: 500 microg/day versus 200 microg/day. Allergol Immunopathol (Madrid) 2008, 36:17-20.
5. Thompson P.J., Wingfield H.J., Cosgrove R.F., et al. Assessment of oral candidiasis in patients with respiratory disease and efficacy of a new nystatin formulation. Br Med J (Clin Res Ed) 1986, 292:1699-1700.
6. Daniluk T., Tokajuk G., Stokowska W., et al. Occurrence rate of oral Candida albicans in denture wearer patients. Adv Med Sci 2006, 51(Suppl. 1):77-80.
7. Selroos O., Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991, 46:891-894.
8. de Vries T.W., Rottier B.L., Visserman H., et al. The influence of inhaled corticosteroids and spacer devices on the growth of respiratory pathogenic microorganisms. Am J Infect Control 2009, 3:237-240.
9. van Rensen E.L., Straathof K.C., Veselic-Charvat M.A., et al. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999, 54:403-408.
10. Phillips K., Oborne J., Lewis S., et al. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004, 59:26-30.
11. Feddah M.R., Brown K.F., Gipps E.M., et al. In-vitro characterisation of metered dose inhaler versus DPI inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci 2000, 3:318-324.
12. Yokoyama H., Yamamura Y., Ozeki T., et al. Analysis of relationship between peak inspiratory flow rate and amount of drug delivered to lungs following inhalation of fluticasone propionate with a diskhaler. Biol Pharm Bull 2007, 30:162-164.
13. Newman S.P. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995, 8(Suppl. 3):S21-S26.
14. Fukushima C., Matsuse H., Tomari S., et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol 2003, 90:646-651.